Display options
Cite
Bocşan CI, Bujor AI, Miron N, et al. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Med J. 2015;32(4):352-8doi: 10.5152/balkanmedj.2015.15884.
Bocşan, C. I., Bujor, A. I., Miron, N., Vesa, �. �. C., Deleanu, D., & Buzoianu, A. D. (2015). In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan medical journal, 32(4), 352-8. https://doi.org/10.5152/balkanmedj.2015.15884
Bocşan, Corina I, et al. "In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial." Balkan medical journal vol. 32,4 (2015): 352-8. doi: https://doi.org/10.5152/balkanmedj.2015.15884
Bocşan CI, Bujor AI, Miron N, Vesa ŞC, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Med J. 2015 Oct;32(4):352-8. doi: 10.5152/balkanmedj.2015.15884. Epub 2015 Oct 01. PMID: 26740893; PMCID: PMC4692333.
Copy Download .nbib Format: NLM
Share it on

Balkan Med J. 2015 Oct;32(4):352-8. doi: 10.5152/balkanmedj.2015.15884. Epub 2015 Oct 01.

In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial.

Balkan medical journal

Corina I Bocşan, Adriana I Bujor, Nicolae Miron, Ştefan C Vesa, Diana Deleanu, Anca D Buzoianu

Affiliations

  1. Department of Clinical Pharmacology, Iuliu Ha?ieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
  2. Department of Allergology, Iuliu Ha?ieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

PMID: 26740893 PMCID: PMC4692333 DOI: 10.5152/balkanmedj.2015.15884

Abstract

BACKGROUND: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties.

AIMS: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 anti-histamines, as well as the risk of asthma after 1.5 years.

STUDY DESIGN: Randomized clinical trial.

METHODS: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients under 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and total symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1β, IL-6, IL-8 and TNF-α.

RESULTS: IL-8 and TNF-α were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p<0.001 and 2.32 vs 1.06, p<0.001, respectively). Both H1 antihistamines reduce all symptoms of allergic rhinitis, including nasal congestion and the plasmatic level of IL-1β, IL-6, IL-8 and TNF-α, after 4 weeks of treatment. The reduction of cytokine levels was not influenced by patients' age, sex, duration or severity of rhinitis, or type of sensitization. Levocetirizine has a superior effect compared to desloratadine in reducing the rhinitis symptoms and cytokines' level. Twenty eight (32.9%) of the patients presented asthma symptoms after 1.5 years. The occurrence of asthma was influenced by house dust sensitization (OR-14.6; CI 95% 1.8-116.3; p=0.01), but baseline values of cytokines were not predictive factors for its appearance.

CONCLUSION: Levocetirizine and desloratadine as a prolonged therapy reduce plasmatic levels of some pro-inflammatory cytokines in patients with PAR. Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1β and IL-8. (ClinicalTrials. gov Identifier: NCT02507635).

FOUNDING: POSDRU and University of Medicine and Pharmacy, Iuliu Haţieganu, Cluj Napoca.

Keywords: Cytokines; allergic rhinitis; histamine H1 antagonists

References

  1. Clin Exp Allergy. 1997 Apr;27(4):379-88 - PubMed
  2. Immunol Res. 2006;34(2):97-115 - PubMed
  3. Pulm Pharmacol Ther. 2007;20(3):244-9 - PubMed
  4. Allergy. 2005 Oct;60(10):1301-7 - PubMed
  5. Clin Ther. 2009 May;31(5):921-44 - PubMed
  6. Int Arch Allergy Immunol. 2012;159(2):171-8 - PubMed
  7. J Allergy Clin Immunol. 2001 Jun;107(6):945-57 - PubMed
  8. J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S486-94 - PubMed
  9. Allergy. 2005 Sep;60(9):1132-8 - PubMed
  10. Clin Exp Allergy. 2004 Jun;34(6):958-64 - PubMed
  11. Clin Exp Allergy. 2002 Apr;32(4):489-98 - PubMed
  12. Am J Rhinol Allergy. 2011 Jul-Aug;25(4):e123-8 - PubMed
  13. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):375-9 - PubMed
  14. Arch Otolaryngol Head Neck Surg. 2010 Aug;136(8):796-800 - PubMed
  15. Allergy. 2008 Mar;63(3):268-73 - PubMed
  16. Am J Respir Cell Mol Biol. 1994 May;10(5):471-80 - PubMed
  17. J Allergy Clin Immunol. 2004 Apr;113(4):669-76 - PubMed
  18. Curr Opin Allergy Clin Immunol. 2003 Feb;3(1):45-50 - PubMed
  19. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):106-8 - PubMed
  20. Clin Transl Allergy. 2013 Feb 01;3(1):3 - PubMed
  21. Inflamm Res. 2003 Apr;52 Suppl 1:S49-50 - PubMed
  22. Int Immunopharmacol. 2005 Dec;5(13-14):1800-8 - PubMed
  23. Respir Med. 2012 Jan;106(1):9-14 - PubMed
  24. Eur Respir J. 2004 Nov;24(5):758-64 - PubMed
  25. Allergy. 2008 Apr;63 Suppl 86:8-160 - PubMed
  26. J Investig Allergol Clin Immunol. 2013;23(3):145-51 - PubMed
  27. Rhinology. 1998 Dec;36(4):156-61 - PubMed
  28. Int Arch Allergy Immunol. 2004 Jul;134(3):227-32 - PubMed
  29. J Allergy Clin Immunol. 2004 Jan;113(1):86-93 - PubMed
  30. Allergy Asthma Immunol Res. 2010 Apr;2(2):65-76 - PubMed

Publication Types